Nano X Imaging Ltd Dossier
Qualitative Analysis
Business overview
Nano-X Imaging Ltd. (NASDAQ: NNOX) is an Israel-based medical imaging technology company focused on democratizing global access to diagnostic imaging. The company's core innovation is the Nanox.ARC, an FDA-cleared and CE-marked multi-source 3D digital tomosynthesis imaging system built on a novel semiconductor cold-cathode technology. This technology aims to significantly reduce the cost and footprint of traditional X-ray equipment. Nano-X operates an integrated, end-to-end platform combining affordable hardware, progressive AI-based solutions (Nanox.AI), cloud-based software (Nanox.CLOUD), and remote radiology services (Nanox.MARKETPLACE). The company operates through three primary business segments: Nanox.ARC, AI and Software Solutions, and Radiology Services, with the majority of its current revenue generated from Radiology Services.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Winding down certain operations at the South Korean facility, closing its chip manufacturing line, and shifting production to external partners (CSEM) while refocusing the South Korean fab as an R&D center.
Expected impact: Aimed at bringing the manufacturing cost base in line with the long-term financial model, improving gross margins, lowering capital expenditures, and reducing ongoing operating expenses and cash burn.
Shifting commercial strategy to scale system placements through regional and national distribution partnerships rather than relying solely on direct sales or pay-per-use models.
Expected impact: Accelerates the commercial footprint and adoption of the Nanox.ARC system across the U.S. and international markets by leveraging established partner networks.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To accelerate the deployment of Nanox's FDA-cleared AI solutions that analyze routine CT scans for chronic diseases. Bringing these healthcare IT integration, workflow optimization, and customer-support capabilities in-house allows Nanox to control the entire customer experience from software delivery through go-live support.
Financial impact: Structured as $200,000 cash at closing and up to $600,000 in performance-based earnouts over two years. Contributed $0.4 million to AI and software revenue in Q4 2025.
Strategic Partnerships
High. Expands Nanox's U.S. channel partner network into traditionally underserved healthcare and public sector markets, providing a scalable framework for commercial rollout.
Terms: Howard Technology Solutions will market and deploy 300 Nanox.ARC systems over a three-year period, with an initial rollout of 60 units in the first year.
High. Integrates Nanox.AI's FDA-cleared software solutions (HealthCCSng, HealthOST, and HealthFLD) into 3DR Labs' portfolio, expanding commercial reach to over 1,800 hospitals and imaging centers across the U.S.
Terms: Commercial reseller agreement approved in accordance with related-party transaction laws (as 3DR's CEO also serves as a director at Nanox).
Medium. Marks a significant milestone in European expansion by leveraging EXRAY's dominant market presence (installations in over 50% of Czech healthcare facilities) to introduce the CE-marked Nanox.ARC system in the Czech Republic.
Terms: EXRAY will lead the market introduction, sales, and service of the Nanox.ARC system in the Czech Republic; financial terms were not publicly disclosed.